Drew Hykes: Thanks.
Mitch Hill: Thank you, Marie.
Operator: The next question is from Bill Plovanic with Canaccord. Please go ahead.
Bill Plovanic: Hi great, thanks good evening. Thanks for taking my questions. I’d like to get a little clarity on the FLAME data that’s coming out in the commentary that this could really change guidelines. And just, Tom, help us understand if we see this data at ACC and it’s super powerful, what is the process in terms of guidelines getting changed, like how long would that take in your opinion? And then how long do you think that takes to flow down to kind of everybody else? And that’s – I’ll have a follow-up – I’ll start with that, please?
Tom Tu: Well, thanks for the question, Bill. So of course, the FLAME study design has been published already. So that is public information. And certainly, anything that affects a baseline mortality of 25% to 50%, I think, could be paradigm shifting in this space. Now we all talk about guidelines and standard of care. And I just want to be a little more particular because those two are not interchangeable. Standard of care is what doctors do. Guidelines are simply, what’s codified in some kind of expert consensus document. And I wouldn’t necessarily portray it as behavior flows down from guidelines. I think it’s a two-way street. It is quite likely that the compelling data that is presented at ACC next week is going to immediately shift behavior patterns of physicians that are already kind of on the cusp of change of practice patterns.
I think guidelines are written by various physician organizations. They all have different schedules on when they meet, how often they meet, how often they update their guidelines, although it is not unheard of for out of sequence meetings to be held and guidelines to be updated when compelling data is presented. So certainly, that could be the case. But we may certainly see behavioral changes well before you see any codification in printed guidelines.
Bill Plovanic: Great. And then just the clarification. I know there’s been obviously a lot of questions around just the guidance, but I just wanted to confirm that — and I heard this right, that January and February were the two best months for the company in its history. Is that accurate?
Drew Hykes: Yes. What we said in the prepared remarks, Bill, were that January and February were among the strongest months we’ve ever had. And obviously, February is not quite over yet, but that’s the way we framed it.
Bill Plovanic: Okay. And then just, again, which I think Mitch’s comment that — and then March is a longer than typical month.
Drew Hykes: Yes, certainly relative to February. And I think the way the calendar shapes up this year, I think there’s even more working days, if you will, in the month of March.
Bill Plovanic: Okay. That’s all I had. Thanks for taking my questions.
Mitch Hill: Thanks Bill. Appreciate it.
Drew Hykes: Thanks Bill.
Operator: The next question is from Mike Sarcone with Jefferies. Please go ahead.
MikeSarcone: Hi, good afternoon. And thanks for taking my questions. The first one, I think, for Mitch. Mitch, you had mentioned when you were talking about ’23 guidance that you also incorporated pricing trends and dynamics. Do you think you can just walk us through how ASP has trended through 4Q and then what you’re expecting in 2023?
Mitch Hill: Yes. We were — we’ve been very pleased with the pricing performance of the business really throughout the year 2022. And so it’s been a stable market for us. And as we’ve added value to the FlowTriever toolkit, and we’re sort of heading in the direction of toolkits for ClotTriever and eventually for chronic venous as well. We’re looking for ways to make sure we can sell based on value rather than sort of price-based competition. And I think we’ve been successful as our hospital contracts roll over to emphasize the value and the kind of the clinical outcomes that the treating physicians are able to game with these products. And as well, we have a — we’re in a nice position because as a lytic free treatment, we’re able to keep patients out of the ICU.
